Aspergillus fumigatus and cystic fibrosis lung disease – the overview
Authors:
M. Zápalka 1; F. Kopřiva 1; V. Raclavský 2
Authors place of work:
Dětská klinika FN a LF UP, Olomouc
přednosta prof. MUDr. V. Mihál, CSc.
1; Ústav mikrobiologie LF UP, Olomouc
přednosta prof. MUDr. M. Kolář, Ph. D.
2
Published in the journal:
Čes-slov Pediat 2015; 70 (6): 342-350.
Category:
Review
Předneseno na pracovním setkání lékařů center CF v ČR, RECYF 2013, 8. 11. 2013, Praha.
Summary
Diagnostics and treatment of mycotic complications is an integral part of care for cystic fibrosis (CF) patients with lung disease. Aspergillus fumigatus is one of the mycotic pathogens we can find in CF patients' airways. The most common manifestation of Aspergillus associated disease is allergic bronchopulmonary aspergillosis (ABPA). It is not an infection in the true sense of the word but a hypersensitive reaction to mycotic antigens. Colonization of the airways with Aspergillus fumigatus causing infection was documented in 2006 for the first time. It was also pointed out that Aspergillus infection has negative influence on lung functions and causes more frequent exacerbations of lung disease. Since then subsequent studies haven't confirmed this observation completely, however they haven't excluded it either and some recommendations for the diagnostics and treatment of this clinical conditions have been published.
The treatment of Aspergillus infections in CF patients remains strictly individual, it doesn't involve corticoid therapy like CF-ABPA. Besides systemic antimycotic treatment, inhalation therapy is used as well. The task of further studies is to confirm whether the mycotic pathogens present a real threat to CF patients as “emergency pathogens” or whether they are only a non-pathogenic colonization of CF patients' airways as a part of the chronic processes.
Key words:
Aspergillus fumigatus, cystic fibrosis, aspergillus bronchitis, allergic bronchopulmonary aspergillosis, ABPA
Zdroje
1. Kolwijck E, van de Veerdonk FL. The potential impact of the pulmonary microbiome on immunopathogenesis of aspergillus-related lung disease. Eur J Immunol 2014; 44 (11): 3156–3165.
2. Liu JC. What is the clinical significance of filamentous fungi positive sputum cultures in patients with cystic fibrosis? J Cyst Fibros 2013; 12 (3): 187–193.
3. Araujo R, Amorim A, Gusmão L. Diversity and specificity of microsatellites within aspergillus section Fumigati. BMC Microbiology 2012; 12: 154.
4. Chotirmall SH. Aspergillus-associated airway disease, inflammation, and the innate immune response. Biomed Res Int 2013.
5. Amitani R, Kawanami R. Interaction of aspergillus with human respiratory mucosa: a study with organ culture model. Med Mycol 2009; 47 (Suppl 1): S127–131.
6. Shoseyov D, Brownlee KG, Conway SP, Kerem E. Aspergillus bronchitis in cystic fibrosis. Chest 2006; 130 (1): 222–226.
7. Speirs JJ. Effects od Aspergillus fumigatus colonization on lung function in cystic fibrosis. Curr Opin Pulm Med 2012; 18 (6): 632–638.
8. Moss RB. Allergic bronchopulmonary aspergilossis and aspergillus infection in cystic fibrosis. Curr Opin Pulm Med 2010; 16 (6): 598–603.
9. Agarwal R. Allergic bronchopulmonary aspergillosis: Review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43 (8): 850–873.
10. Heribanová L. Alergická bronchopulmonální aspergilóza. Prakt Lék 2014; 94 (2): 59–63.
11. Koo S, Thomas HR, Daniels SD, et al. A breath fungal secondary metabolite signature to diagnose invasive aspergillosis. Clin Infect Dis 2014; 59 (12): 1733–1740.
12. Aaron SD, Vandemheen KL, Freitag A, et al. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS One 2012; 7.
13. Middleton PG: Fungal infections and treatment in cystic fibrosis. Curr Opin Pulm Med 2013; 19 (6): 670–675.
14. Baxter CG. Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol 2013; 132 (3): 560–566.
15. Wilmott R. Kendig and Chernick’s Disorders of the Respiratory Tract in Children. 8th ed. Elsevier 2012. ISBN: 978-1-4377-1984-0.
16. Hayes D Jr. Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis. Pediatr Pulmonol 2010; 45 (11): 1145–1148.
17. Proesmans M. Use of nebulized amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Int J Pediatr 2010; 287.
18. Tanou K. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis. A synthesis of published evidence. Pediatr Pulmonol 2013; 25.
19. Lehmann S, Pfannenstiel C, Friedrichs F, et al. Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Ther Adv Respir Dis 2014; 8 (5): 141–149.
Štítky
Neonatology Paediatrics General practitioner for children and adolescentsČlánok vyšiel v časopise
Czech-Slovak Pediatrics
2015 Číslo 6
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Primary (autoimmune) sclerosing cholangitis in patient with inflammatory bowel disease
- Nicotine alters brain development
- Influence of heel valgus on foot motion during walking in children aged 3–8 years
- Aspergillus fumigatus and cystic fibrosis lung disease – the overview